AbstractAspirin-pretreated, 32P-prelabeled, washed human platelets resuspended in a buffer containing apyrase and 2% plasma were exposed to epinephrine and the Ca2+ ionophore A23187. Epinephrine potentiated platelet aggregation (not secretion), the production of [32P]phosphatidic acid and myosin light chain phosphorylation induced by A23187. No phosphorylation of the 40 kDa protein, the substrate of protein kinase C, was observed. We conclude that G1-protein activation evoked by epinephrine and Ca2+ mobilization caused by A23187 represents a novel synergism for platelet aggregation and that protein kinase C activation, under these conditions is not needed for platelet aggregation
AbstractSimultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergi...
AbstractIt has recently been suggested that the concomitant activation of two distinct G protein-cou...
AbstractSimultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergi...
AbstractAspirin-pretreated, 32P-prelabeled, washed human platelets resuspended in a buffer containin...
Platelet activation is characterized by shape change, granule secretion, activation of fibrinogen re...
Platelet activation is characterized by shape change, granule secretion, activation of fibrinogen re...
AIM: To investigate the mechanism (s) involved in the synergistic interaction of platelet activating...
AIM: The present study deals with the investigation of mechanisms involved in the synergistic intera...
AIM: The present study deals with the investigation of mechanisms involved in the synergistic intera...
AIM: To investigate the mechanism (s) involved in the synergistic interaction of platelet activating...
Although it is well established that G(q)- and G(i)-coupled receptors can combine to mediate platele...
Although it is well established that G(q)- and G(i)-coupled receptors can combine to mediate platele...
AbstractU46619 is a potent platelet agonist, its binding to the thromboxane A2 receptor resulting in...
International audienceTicagrelor, an antagonist of the platelet adenosine diphosphate (ADP)-P2Y(12) ...
International audienceTicagrelor, an antagonist of the platelet adenosine diphosphate (ADP)-P2Y(12) ...
AbstractSimultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergi...
AbstractIt has recently been suggested that the concomitant activation of two distinct G protein-cou...
AbstractSimultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergi...
AbstractAspirin-pretreated, 32P-prelabeled, washed human platelets resuspended in a buffer containin...
Platelet activation is characterized by shape change, granule secretion, activation of fibrinogen re...
Platelet activation is characterized by shape change, granule secretion, activation of fibrinogen re...
AIM: To investigate the mechanism (s) involved in the synergistic interaction of platelet activating...
AIM: The present study deals with the investigation of mechanisms involved in the synergistic intera...
AIM: The present study deals with the investigation of mechanisms involved in the synergistic intera...
AIM: To investigate the mechanism (s) involved in the synergistic interaction of platelet activating...
Although it is well established that G(q)- and G(i)-coupled receptors can combine to mediate platele...
Although it is well established that G(q)- and G(i)-coupled receptors can combine to mediate platele...
AbstractU46619 is a potent platelet agonist, its binding to the thromboxane A2 receptor resulting in...
International audienceTicagrelor, an antagonist of the platelet adenosine diphosphate (ADP)-P2Y(12) ...
International audienceTicagrelor, an antagonist of the platelet adenosine diphosphate (ADP)-P2Y(12) ...
AbstractSimultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergi...
AbstractIt has recently been suggested that the concomitant activation of two distinct G protein-cou...
AbstractSimultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergi...